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Fourteen days of smoking 
cessation improves muscle fatigue 
resistance and reverses markers 
of systemic inflammation
Mohammad Z. Darabseh 1*, Thomas M. Maden‑Wilkinson2, George Welbourne1, 
Rob C. I. Wüst 3, Nessar Ahmed4, Hakima Aushah5, James Selfe6, Christopher I. Morse7 & 
Hans Degens1,8
Cigarette smoking has a negative effect on respiratory and skeletal muscle function and is a risk factor 
for various chronic diseases. To assess the effects of 14 days of smoking cessation on respiratory 
and skeletal muscle function, markers of inflammation and oxidative stress in humans. Spirometry, 
skeletal muscle function, circulating carboxyhaemoglobin levels, advanced glycation end products 
(AGEs), markers of oxidative stress and serum cytokines were measured in 38 non‑smokers, and 
in 48 cigarette smokers at baseline and after 14 days of smoking cessation. Peak expiratory flow 
(p = 0.004) and forced expiratory volume in 1 s/forced vital capacity (p = 0.037) were lower in smokers 
compared to non‑smokers but did not change significantly after smoking cessation. Smoking 
cessation increased skeletal muscle fatigue resistance (p < 0.001). Haemoglobin content, haematocrit, 
carboxyhaemoglobin, total AGEs, malondialdehyde, TNF‑α, IL‑2, IL‑4, IL‑6 and IL‑10 (p < 0.05) levels 
were higher, and total antioxidant status (TAS), IL‑12p70 and eosinophil numbers were lower (p < 0.05) 
in smokers. IL‑4, IL‑6, IL‑10 and IL‑12p70 had returned towards levels seen in non‑smokers after 
14 days smoking cessation (p < 0.05), and IL‑2 and TNF‑α showed a similar pattern but had not yet 
fully returned to levels seen in non‑smokers. Haemoglobin, haematocrit, eosinophil count, AGEs, 
MDA and TAS did not significantly change with smoking cessation. Two weeks of smoking cessation 
was accompanied with an improved muscle fatigue resistance and a reduction in low‑grade systemic 
inflammation in smokers.
Cigarette smoking still is a public health concern and a risk factor for many chronic diseases, including chronic 
obstructive pulmonary disease (COPD), lung cancer and cardiovascular  diseases1,2. It is the leading cause of 
preventable death and 77,900 deaths in the United Kingdom were directly or indirectly attributable to smoking 
in 2016 3. In England, between 2017 and 2018, an estimated 489,300 smoking-related admissions to hospitals 
were  reported4.
The adverse health effects are a consequence of a combination of thousands of toxic and/or carcinogenic sub-
stances, including carbon monoxide (CO), reactive glycation compounds, known as glycotoxins, and nicotine in 
cigarette  smoke5–7. In addition, the low-grade systemic inflammation and oxidative stress in smokers increases the 
risk of  atherosclerosis8–12. Smoking is associated with elevated serum cholesterol and triglyceride levels, impaired 
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glucose tolerance and reduced insulin  sensitivity13. It has been reported that in diabetic people, a reduced insu-
lin sensitivity could lead to glycation of myofibrillar  proteins14 that may be further aggravated by glycotoxins 
in cigarette smoke that can also react with serum proteins to form advanced glycation end products (AGEs)6.
In addition to the health burden of cigarette smoking and the potential adverse effect on respiratory 
 function15,16, smoking can also have a negative impact on muscle  function17–19. Part of the potential detrimental 
effect of cigarette smoking may be attributable to the negative impact on the oxygen delivery to tissues, includ-
ing skeletal muscles, that may in turn result in exercise intolerance and a reduced muscle fatigue  resistance20–22. 
Such an impaired oxygen delivery is at least partly attributable to the CO in the cigarette smoke that strongly 
binds to haemoglobin (Hb), forming carboxyhaemoglobin (COHb)23. This not only reduces the oxygen carrying 
capacity of the blood, but also causes a left-shift of the Hb-dissociation curve. The significance of elevated COHb 
levels has been illustrated by an acute CO-induced reduction in muscle fatigue resistance in healthy  people24. 
In addition, CO and cyanide may also directly impair mitochondrial  respiration25,26. As fatigue resistance was 
similar in COPD patients who had quit smoking and healthy age-matched non-smokers27, we hypothesised that 
the effect of smoking on skeletal muscle fatigue is readily reversible by smoking cessation .
Smoking cessation is an important step to stop or reverse many of the detrimental effects of smoking and 
is considered a highly effective way to reduce morbidity and  mortality28 and slow down the accelerated decline 
in  FEV129,30. In fact, smoking cessation is considered one of the main actions to attenuate the progression of 
 COPD31,32. In line with this, it has been seen in mice, that the smoking-induced lung inflammation, mitochon-
drial dysfunction, limb and diaphragm muscle atrophy, and elevated IL-1α and TNF-α levels were normalised 
after smoking  cessation26,33. In addition, if CO is an important cause of a reduced muscle fatigue resistance and 
exercise tolerance, we expect that smoking cessation, resulting in a quick normalisation of the COHb  levels34, will 
be associated with a concomitant improvement in muscle function. Therefore, we hypothesise, that just two weeks 
of smoking cessation is sufficient to detect measurable improvements in muscle fatigue resistance, and diminished 
levels of circulating inflammatory markers and oxidative stress. As there is some indication that smoking may 
cause a larger reduction in pulmonary function than in  men35 and that women have a higher muscle fatigue 
resistance than  men36 we were also interested in potential sex differences in the response to smoking cessation.
Methods
Participants. Cigarette smokers (men n = 28; women n = 20) and non-smokers (men n = 23; women n = 15) 
were recruited from the local community and Manchester Metropolitan University (MMU). Participants were 
18 to 44 years old, and smokers had smoked for ≥ 1 year and ≤ 17 years. All participants self-reported as being 
free of symptoms of chronic diseases. In cigarette smokers, all measurements were repeated after 14 days of 
smoking cessation. The study was approved by the Science and Engineering Research Ethics and Governance 
Committee at MMU (Ethics reference number: 5944) and performed in accordance to the principles stated in 
the Declaration of Helsinki. All participants provided written informed consent before participating.
Height and body mass were assessed using a stadiometer and digital scales, respectively. Body mass index 
(BMI) was calculated. Smoking history was assessed by questionnaire. Smoking volume (SV) was given as pack 
years, calculated as the current number of packs of cigarettes smoked per day times the number of years smoked.
Outcome measures. Carboxyhaemoglobin (COHb). A hand-held CO meter (Micro Smokerlyzer, Bed-
font Scientific Ltd.; Kent, UK) was used to measure the percentage of the haemoglobin (Hb) oxygen binding 
sites occupied by CO (%COHb). The measurements were performed according to the recommendations of the 
 manufacturer37.
Spirometry. Spirometry was conducted using a Micro Medical Spiro USB Spirometer and analysed with Spida 
5 software (Cardinal Health, UK). Spirometry was completed in accordance with the American Thoracic Soci-
ety and European Respiratory Society  guidelines38. Each participant completed a minimum of three successful 
manoeuvres with at least 1–2 min rest between each manoeuvre while wearing a nose clip. The manoeuvres 
were rejected if: participants prematurely stopped exhalation, coughed during the first second of exhalation, 
lips were not fully sealed around the mouthpiece and/or the effort appeared submaximal. The test session was 
concluded when the largest two  FEV1 and the largest two FVC were each within 0.15 L of each other in at least 
3  manoeuvres38. If these criteria were not met, a maximum of eight manoeuvres were repeated until the criteria 
were met. Parameters assessed included:  FEV1, FVC,  FEV1/FVC ratio, Peak Expiratory Flow (PEF), and pre-
dicted values. The coefficient of variation (CV) for  FEV1, FVC and PEF was 2.09%, 2.25% and 2.80%, respectively.
Maximal voluntary contraction (MVC). A dynamometer chair was used to measure the MVC during knee 
extension. Participants were seated with the hip joint in 90° flexion, knee joint angle at 80° and the pelvis 
strapped to minimise accessory movements. All the measurements were performed on the right thigh. During 
the MVC, participants received verbal encouragement and visual feedback of the torque  signal18,19,24,27. Par-
ticipants performed the MVC twice with two minutes rest between each contraction to prevent development 
of fatigue. Knee extensor (KE) torque was recorded with a digital acquisition system (Acknowledge, Biopac 
Systems, Santa Barbara, CA, USA) at 200 Hz, and the highest value was reported as maximal muscle  strength18. 
The CV for the MVC was 4.24%.
Voluntary activation (VA) and muscle fatigue resistance. To assess the VA and muscle fatigue resist-
ance of the quadriceps muscle, carbon–rubber pads (7.5 cm × 13 cm, Axelgaard, USA) were used to apply per-
cutaneous electrical stimulation (square wave, pulse width 200 μs; DSV Digitimer Stimulator, Digitimer Ltd., 
Herts, UK). The cathode was placed over the distal third of the thigh and the anode over the proximal part of 
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the quadriceps. The electrical stimulation voltage was set at 400 V. To assess the supra-maximal current, single 
pulses were administered at 30-s intervals with increases in current of 50–100 mA to the relaxed muscle until no 
further increase in torque was noticed.
To assess the VA during an MVC, the interpolated twitch technique was  used18,19 and calculated as:
and had a CV of 5.96%.
The fatigue resistance of the quadriceps muscles was determined by a series of electrically-evoked isometric 
30-Hz trains, 1 s on 1 s off, for 2 min at a current that elicited 30% MVC at the start of the  test19,27. The fatigue 
index (FI) was calculated as the final torque as a percentage of the initial torque during the series of the isometric 
contractions. The CV was 6.44%.
Haematology parameters and oxidative stress biomarkers. From 9 non-smokers and 20 smokers 
venous blood was collected from the antecubital vein and repeated after 2 weeks of smoking cessation from 
smokers only. After determination of the haematocrit (%Hct) the blood was collected in 4-mL vacutainers with-
out anticoagulants (BD Vacutainer, Becton Dickinson Company, USA). The blood samples were allowed to clot 
for 15 min and serum was separated from whole blood by centrifugation (20 min; 500 × g) at room temperature. 
Following centrifugation, the serum was aliquoted in 1-mL microcentrifuge tubes, frozen and stored at − 80 °C 
until further analysis.
Serum protein, albumin and glucose concentrations were measured colourimetrically using Biuret reagent 
Randox kits using RandoxRX Daytona analyser (Randox Laboratories Ltd., Belfast, Ireland). The glucose con-
centration was determined after enzymatic oxidation in the presence of glucose oxidase. The Hb concentration 
was determined with a HemoCue (HemoCue® Hb 201 + System). Blood cell counts included agranulocytes (lym-
phocytes, monocytes) and granulocytes (neutrophils, eosinophils and basophils). Serum cytokines levels were 
quantified using flow cytometry. Briefly, positive and negative controls were used to set up the flow cytometer 
(BD FACScalibur, Becton Dickinson Company, USA) and analysed using the high flow setting (FL2 channel), 
using Cell Quest Pro software and flowcytomix software. The software translated the flow cytometric results 
into cytokine concentrations (pg  mL−1). Serum malondialdehyde (MDA), a marker of lipid peroxidation, was 
quantified spectrophotometrically using a lipid peroxidation kit (Oxford Biomedical Research, UK). The serum 
total antioxidant status (TAS) in was analysed using the TAS kit (Randox Laboratories Ltd., Belfast, Ireland) 
according to the recommendations by the manufacturer. The abundance of low molecular weight (LMW) AGEs 
were assessed using a spectrofluorimeter (BioTek, USA), and total AGEs were assessed by ELISA (Cell Biolabs, 
United States). All tests were carried out in duplicate and averaged.
Statistical analysis. Statistical analyses were performed using SPSS 24.0 (IBM Corporation, NY, US). Data 
were assessed for normality with the Shapiro–Wilk tests. If the data were not normally distributed, non-par-
ametric Kruskal–Wallis H test was performed. A two-way univariate ANOVA with as between factors group 
(smokers, non-smokers and smoking cessation) and sex was used. If a significant group effect, or a group * sex 
interaction was found, a Dunnet post-hoc test with as standard group the smokers was performed to locate the 
significant differences. For the blood parameters, comparisons between smokers and non-smokers, and com-
parison of smokers before and after cessation were performed with unpaired student t-tests. Differences were 
considered significant at p < 0.05. All data are presented as mean ± SD.
Results
Anthropometric details of the participants are presented in Table 1. The smoking women in our study had 
smoked longer and had smoked more pack years than the smoking men (p < 0.05; Table 1). For none of the 
parameters group * sex interactions were found, indicating that there were no significant differences in the 
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Table 1.  Demographic data. All data are presented as mean ± SD; BMI: body mass index; *: significantly 
different from men at p < 0.05.
Cigarette smokers Non-smokers
Men (n = 28) Women (n = 20) Men (n = 23) Women (n = 15)
Age (years) 25.4 ± 6.0 31.0 ± 12.8* 26.3 ± 10.5 24.8 ± 7.4
Height (m) 1.78 ± 0.09 1.65 ± 0.09* 1.79 ± 0.07 1.65 ± 0.06*
Mass (kg) 77.5 ± 17.7 67.9 ± 11.4* 77.3 ± 11.6 68.2 ± 14.2*
BMI (kg/m2) 24.2 ± 4.5 25.1 ± 4.0 24.1 ± 3.1 24.8 ± 4.3
Smoking duration (years) 7.4 ± 4.3 13.7 ± 12.2* – –
Cigarettes per day 12.3 ± 6.0 12.7 ± 5.7 – –
Smokers pack-years 4.6 ± 2.9 9.6 ± 11.0* – –
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The total protein, albumin and glucose concentrations did not differ significantly between smokers and non-
smokers (Table 2). Smokers had higher levels of COHb than non-smokers (p < 0.001) and the COHb levels had 
returned to levels similar to that in non-smokers after 14 days of smoking cessation (Table 3).
Spirometry. PEF,  FEV1 and FVC were higher in men than women (p < 0.001), but  FEV1/FVC,  FEV1pred%, 
 FVCpred% and  PEFpred% did not differ significantly between men and women (Table  4). There was no signifi-
cant difference in  FEV1,  FEV1pred%,  FVCpred% and  PEFpred% between smokers and non-smokers (Table  4), but 
PEF (p = 0.004; Table 4) and  FEV1/FVC (p = 0.037; Fig. 1) were lower in smokers than in non-smokers. Neither 
changed significantly over the 14 days of smoking cessation (p > 0.05; Fig. 1 and Table 4).
Muscle function. Knee extension MVC was higher in men than women (p < 0.001; Table 4) and FI was 
higher in women than men (p < 0.001), but there were no significant sex differences in VA (p = 0.096; Table 4). 
There was no significant difference in MVC and VA between smokers and non-smokers (Table  4). While 
there was no significant difference in FI between smokers and non-smokers, smoking cessation resulted in an 
increased FI (p < 0.001; Fig. 2).
Haematology. There were no significant differences in total white blood cell, neutrophil, lymphocyte, 
monocyte and basophil counts between smokers and non-smokers (Table 3). The eosinophil count was lower 
in smokers than non-smokers (p < 0.05) even after 14 days smoking cessation (Table 3). Smokers had a higher 
haemoglobin concentration and haematocrit than non-smokers (p < 0.001) and was not changed significantly 
after 14 days of smoking cessation (Table 3).
Circulating markers of oxidative stress. The total antioxidant status was lower in smokers than non-
smokers (p < 0.001) and was not significantly changed after 14 days of smoking cessation (Fig. 3a). Lipid peroxi-
dation, in the form of the concentration of MDA was higher in smokers compared to non-smokers (p < 0.001) 
and were not significantly changed after 14 days of smoking cessation (Fig. 3b). Although the low molecular 
weight AGE levels did not differ significantly between smokers and non-smokers (Fig. 3c), the total AGE levels 
were higher in smokers compared to non-smokers (p < 0.05; Fig. 3d). Smoking cessation did not have a signifi-
cantly alter the concentration of AGEs (Fig. 3c,d).
Table 2.  Smoking or smoking cessation did not alter total protein, albumin and glucose serum concentration. 
All data are presented as mean ± SD; C: Non-smokers; S: smokers; SC: 14 days smoking cessation; NS: not 
significant.
Serum concentrations Non-smokers n = 9 Smokers n = 20 Stop smoking n = 20
Statistical evaluation (p-value)
S versus C S versus SC SC versus C
Total protein (g/L) 65.4 ± 2.3 66.0 ± 3.5 64.5 ± 2.7 NS NS NS
Albumin (g/L) 43.4 ± 2.8 45.7 ± 2.4 44.7 ± 2.3 NS NS NS
Glucose (mmol/L) 5.14 ± 0.75 5.10 ± 0.34 5.33 ± 1.03 NS NS NS
Table 3.  The impact of smoking and smoking cessation on white blood cell counts, haematocrit, haemoglobin 
and carboxyhaemoglobin. All data are presented as mean ± SD; WBC: White blood cells; Hct: Haematocrit; 
COHb: Carboxyhaemoglobin; C: Non-smokers; S: smokers; SC: 14 days smoking cessation; NS: not significant.
Parameters Non-smokers n = 9 Smokers n = 20 Stop smoking n = 20
Statistical evaluation (p-value)
S versus C S versus SC SC versus C
WBC  (109/L) 6.70 ± 2.16 6.98 ± 1.97 6.89 ± 1.70 NS NS NS
Granulocytes
Neutrophil (%) 54.6 ± 4.80 60.3 ± 12.1 58.9 ± 8.50 NS NS NS
Eosinophil (%) 3.44 ± 0.87 2.24 ± 1.03 2.25 ± 0.98  < 0.05 NS  < 0.05
Basophil (%) 1.67 ± 0.87 1.17 ± 0.94 1.42 ± 0.85 NS NS NS
Agranulocytes
Lymphocyte (%) 34.3 ± 3.60 30.5 ± 11.18 32.2 ± 8.05 NS NS NS
Monocyte (%) 6.0 ± 1.23 5.58 ± 1.39 5.58 ± 1.30 NS NS NS
Haematocrit, haemoglobin and carboxyhaemoglobin
Hct (%) 41.0 ± 4.6 46.5 ± 2.6 45.6 ± 2.6  < 0.001 NS  < 0.01
Haemoglobin (g/dL) 13.7 ± 1.80 15.5 ± 0.89 15.3 ± 0.89  < 0.001 NS  < 0.01
COHb (%) 0.07 ± 0.03 2.26 ± 1.08 0.1 ± 0.28  < 0.001  < 0.001 NS
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Table 4.  The effect of smoking and smoking cessation on spirometry, maximal isometric voluntary knee 
extension torque (KE MVC) and voluntary activation (VA). All data are presented as mean ± SD;  FEV1: Forced 
expiratory volume in one second; FVC: Forced vital capacity; PEF: Peak expiratory flow; PEF pred (%): PEF 
predicted percentage; (x) denotes number of participants. Significant effects are denoted in bold; NS: not 
significant.




smokers M 4.4 ± 0.7 (19)
95.9 ± 8.9 
(19)
5.20 ± 0.85 
(19)
93.4 ± 8.9 
(19)
9.90 ± 1.5 
(19)
97.9 ± 13.4 
(19) 257 ± 66 (14)
94.1 ± 6.8 
(14)
Non-
smokers W 3.3 ± 0.4 (14)
98.1 ± 10.9 
(14)
3.89 ± 0.50 
(14)
98.1 ± 9.6 
(14) 7.3 ± 1.2 (14)
98.6 ± 12.5 
(14) 175 ± 24 (8)




4.2 ± 0.7 (21) 92.7 ± 11.8 (21)
5.09 ± 0.8 
(21)
93.6 ± 10.1 
(21)
9.00 ± 1.5 
(21)
90.0 ± 14.1 
(21) 238 ± 62 (21)
85.3 ± 14.2 
(20)
Stop smok-
ing 4.1 ± 0.8 (7)
90.0 ± 15.7 
(7) 5.03 ± 1.0 (7)
90.3 ± 13.1 
(7) 9.80 ± 1.9 (7)
95.6 ± 19.8 
(7) 270 ± 51 (13)




3.0 ± 0.419) 92.0 ± 11.0 (19)
3.61 ± 0.4 
(19)
93.2 ± 9.2 
(19)
6.30 ± 1.2 
(19)
89.6 ± 16.0 
(19) 149 ± 37 (13)
94.8 ± 7.3 
(13)
Stop smok-
ing 2.9 ± 0.5 (8)
91.4 ± 12.6 
(8) 3.49 ± 0.4 (8)
91.6 ± 12.6 
(8) 6.50 ± 1.1 (8)
90.1 ± 18.2 
(8) 150 ± 33 (9) 95.8 ± 4.9 (9)
P-value
Smoke NS NS NS NS 0.004 NS NS NS
Sex  < 0.001 NS  < 0.001 NS  < 0.001 NS  < 0.001 NS
Figure 1.  The effect of smoking and 14 days smoking cessation on  FEV1/FVC: Forced expiratory volume in one 
second/forced vital capacity; data are mean ± SD; *: significantly different from Non-smokers at p < 0.05.
Figure 2.  The effect of smoking and 14 days smoking cessation on fatigue index. Data are mean ± SD; ∞: 
significantly different from men at p < 0.05; α: significantly different from smokers at p < 0.05.
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Circulating levels of cytokines. Smokers had higher circulating levels of TNF-α, IL-2, IL-4, IL-6 and 
IL-10 levels than non-smokers (All p < 0.001; Fig. 4a–e), while IL-12p70 levels were lower in smokers than in 
non-smokers (p < 0.001; Fig. 4f). Almost all circulating cytokines concentrations returned to levels seen in non-
smokers after 14 days of smoking cessation, except for TNF-α and IL-2 that though reduced, where still ele-
vated in comparison to non-smokers (p < 0.05; Fig. 4a,b). TNF-β, IFN-γ, IL-1β, IL-5 did not differ significantly 
between smokers and non-smokers (Table 5).
Discussion
The main observation of the present study was that in smokers with normal spirometry 14 days of smoking 
cessation resulted in a normalisation of skeletal muscle fatigue resistance and a return of circulating markers of 
inflammation. This indicates that even as little as 14 days of smoking cessation can confer measurable benefits 
that may encourage smokers in their smoking cessation efforts.
Differences between smokers and non‑smokers. Spirometry. The present study confirms that  FEV1, 
FVC and PEF were higher in men than  women39. The spirometry in smokers was similar to that of non-smokers, 
except for a lower  FEV1/FVC, indicative of some minor developing airway obstruction.
Muscle function. In line with previous  observations18,19,40, we found that the maximal strength of the knee 
extensor muscles in smokers was similar to that in non-smokers. Others, however, have reported a lower force 
generating capacity in  smokers41–44. Although part of a lower strength may at least in theory be attributable to a 
lower ability to voluntarily activate the muscle, we found no difference in voluntary activation between smok-
ers and non-smokers, and if anything, even an increased VA has been reported in  smokers19. The latter may be 
the result of an increased sympathetic nerve activity in smokers, possibly due to a central stimulant action of 
 nicotine45,46. Whatever the cause of the discrepancy between studies concerning the impact of smoking on the 
MVC, it indicates that smoking per se is not necessarily associated with muscle weakness.
Somewhat unexpected was the absence of lower fatigue resistance in smokers that was seen in previous studies 
using the same fatigue  protocol18,19. This reduced fatigue resistance in the previous smokers was thought to be 
at least partly attributable to elevated COHb levels, seen also in the current and other  studies23,47 that not only 
reduces the oxygen carrying capacity, but also the release of oxygen due to the left-shift of the Hb-dissociation 
 curve17,24. It should be noted, however, that 6% COHb reduced skeletal muscle fatigue  resistance24 and the 3% 
COHb in our participants may not have had a measurable impact on the oxygen delivery to the skeletal muscle, 
and hence the fatigue resistance.
Blood parameters. While we did not see a significant difference in the albumin and total protein concen-
trations in the blood of smokers and non-smokers, others did see that smokers had a lower total protein and 
albumin concentration compared to non-smokers48 or even a higher protein  concentration49. Consistent with 
previous  studies50–52, the haemoglobin concentration and haematocrit were higher in smokers compared to non-
smokers. The higher haemoglobin concentration may well be an adaptation to maintain the oxygen carrying 
capacity in the face of elevated COHb  levels53,54.
Although there were no significant differences in monocytes and lymphocytes between smokers and non-
smokers in the current and previous  studies52,55, except for a reduction in the number of eosinophils, we observed 
Figure 3.  Effects of smoking and 14 days smoking cessation. (a) Total antioxidant status (TAS); (b) 
Malondialdehyde concentration; (c) Low molecular weight (LMW) advanced glycation end products (AGEs) 
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a significant increase in TNF-α, IL-2, IL-4, IL-6 and IL-10. This suggests that smoking activates mononuclear 
cells to release cytokines. In line with this, it has been observed that cigarette smoke induces the release of TNF-α 
in an in vitro macrophage model  system56, but others found no increased release of TNF-α peripheral blood 
mononuclear cells to cigarette smoke  extracts57. It should be noted, however, that TNF-α is not only produced 
by blood mononuclear cells, but also by epithelial cells, fibroblasts and smooth muscle  cells58, p. 229 and perhaps 
mononuclear and epithelial cells in the lung of  smokers59. In line with this, it has been observed that there was a 
significantly elevated number of macrophages and neutrophils in the broncheo-alveolar lavage fluid of smoking 
 mice26. Therefore, lung-derived cytokines may well be the prime explanation of the higher TNF-α, IL-2, IL-4, 
IL-6 and IL-10 concentrations and the lower level of the anti-inflammatory IL-12p70 concentration in smokers 
than non-smokers, indicating that even young-adult asymptomatic smokers suffer from a low-grade systemic 
inflammation.
Figure 4.  Effects of smoking and 14 days smoking cessation (a) TNF-α: tumour necrosis factor-alpha; (b) IL-2: 
interleukin-2; (c) IL-4: interleukin-4; (d) IL-6: interleukin-6; (e) IL-10: Interleukin-10; (f) IL-12p70: interleukin-
12p70; data are presented as mean ± SD; *: significantly different from Non-smokers at p < 0.05; α: significantly 
different from smokers at p < 0.05.
Table 5.  The impact of smoking and smoking cessation on circulating cytokines. All data are presented as 
mean ± SD; TNF-β: tumour necrosis factor-beta; INF-γ: interferon-gamma; IL-1β: interlukin-1beta; IL-5: 
interleukin-5; C: Non-smokers; S: smokers; SC: 14 days smoking cessation; NS: not significant.
Cytokines (pg/mL) Non-smokers n = 9 Smokers n = 20 Stop smoking n = 20
Statistical evaluation (p-value)
S versus C S versus SC SC versus C
TNF-β 82.9 ± 31.2 109.0 ± 34.0 109.1 ± 46.8 NS NS NS
IFN-γ 139 ± 82 144 ± 57 161 ± 55 NS NS NS
IL-1β 100.4 ± 53.0 109.4 ± 38.4 94.1 ± 41.3 NS NS NS
IL-5 109 ± 89 125 ± 57 132 ± 30 NS NS NS
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It is possible that the lower TAS and higher MDA levels in smokers, also reported by  others60, may be due 
to this low-grade systemic inflammation. The oxidative stress in smokers may well have contributed to their 
elevated AGE  levels6,61,62. Although AGEs are often considered to represent indirectly a high level of  glucose63,64, 
we and  others49 did not find elevated glucose levels in smokers. It should be noted that not only high glucose 
concentrations, but also toxic constituents of cigarette smoke might induce glycotoxins that rapidly react with 
protein to form  AGE6. Therefore, we suggest that the increased AGEs in asymptomatic young-adult smokers is 
primarily attributable to glycotoxins, oxidative stress, and to some extent secondary to the low-grade systemic 
inflammation.
Smoking cessation. Spirometry. The present study showed that 14 days of smoking cessation did not re-
sult in an improvement in the smoking-induced decrement of  FEV1/FVC. This is supported by numerous studies 
suggesting that pulmonary changes induced by smoking are irreversible, even though smoking cessation is the 
best approach to stop the accelerated decline in lung function in  smokers65–70.
Muscle function. In support of our hypothesis, we found an improved skeletal muscle fatigue resistance 
after 14  days of smoking cessation that was accompanied with a return of the COHb levels to that seen in 
non-smokers. It therefore does appear that the improved fatigue resistance after smoking cessation was at least 
to some extent attributable to an improved oxygen delivery, and perhaps also improved mitochondrial func-
tion. Indeed, 2 weeks smoking cessation has been shown to improve mitochondrial function in mouse muscle, 
although in mice this was not accompanied by an improved muscle fatigue  resistance26. Nevertheless, our data 
suggest that even in smokers with only 3% COHb smoking cessation can still enhance muscle fatigue resistance, 
even when the fatigue resistance was not significantly less than that in non-smokers. Perhaps the enhanced 
fatigue resistance after smoking cessation is to some extent also attributable to the elevated haemoglobin concen-
tration and haematocrit that enhance the oxygen carrying capacity and oxygen delivery with smoking cessation 
even above that seen in the non-smokers17,53, similar to that seen after doping with  erythropoietin71. In addition, 
smoking cessation also improves exercise-induced  vasodilation72,73. Overall, our data indicate that even smoking 
cessation for as short a period as 2 weeks can result in measurable improvements in muscle fatigue resistance.
Blood parameters. Another significant observation in our smokers was evidence of low-grade systemic 
inflammation and oxidative stress. It was therefore particularly interesting to assess the impact of smoking ces-
sation on these parameters. Here we found that most of the abnormal blood parameters were normalised by 
14 days of smoking cessation.
The present study showed that both TAS and MDA did not return to normal levels after 14 days of smoking 
cessation. This may occur later as it has been shown that after 28 days of smoking cessation, TAS was increased 
and MDA levels reduced back to normal  levels74. AGE levels also did not show a significant decrement after 
14 days of smoking cessation. The 3-week half-life of  AGEs75–77 may explain that despite the diminished low-
grade systemic inflammation AGEs remained elevated. Therefore, 14 days of smoking cessation might not be 
long enough to cause a normalisation in TAS, MDA and AGEs to levels similar to that in non-smokers.
Smoking cessation interrupts the exposure to chemicals in cigarette smoke 28 and it is likely that the reduced 
concentration of smoking-related chemicals in the blood that induce inflammation will result in a reduction in 
cytokine  levels78–80. For example, the elevated levels of TNF-α after 20 weeks smoking was back to baseline levels 
after 8 weeks smoking cessation in the broncho-alveolar lavage fluid of  mice33 and similarly 30 days smoking 
cessation resulted in a significant reduction in TNF-α in  humans28. Here we showed that IL-6, IL-10, IL-12p70, 
IL-4 returned to normal levels and TNF-α was reduced after 14 days of smoking cessation. It has been suggested 
that the lungs are the primary cause of the low-grade systemic inflammation in patients with chronic obstructive 
pulmonary  disease81. In line with this it has been shown that 2 weeks smoking cessation in mice led to a return in 
the number of leucocytes in the broncheo-alveolar lavage fluid to normal  levels26. Eosinophil numbers remained 
lower in smokers than non-smokers after 14 days of smoking cessation, which may be secondary to the higher 
concentration of IL-2 in smokers, even after 14 days of smoking cessation.
Future directions. We showed significant improvements in muscle fatigue resistance and inflammatory 
status that may well be sufficient to stimulate smokers in their attempts to quit smoking. Future studies are 
recommended to conduct longer duration of smoking cessation programmes with larger sample size to assess 
whether also the markers of oxidative stress and circulating AGEs return to normal values. Although it remains 
to be seen to what extent the effects observed are related to the duration of smoking, in our previous work we 
have shown that at least the lower fatigue resistance in smokers was not related to the duration of smoking or 
smoking pack  years19.
Conclusion
Even in smokers with normal spirometry there is significant evidence of oxidative stress and systemic inflamma-
tion. A short period of smoking cessation of just 2 weeks is enough to improve the inflammatory status to almost 
back to normal levels and induce an improvement in muscle fatigue resistance. These benefits will undoubtedly 
stop the progression of detrimental effects of low-grade systemic inflammation and encourage smokers in their 
attempts to quit smoking.
Data availability
When appropriate and reasonable, anonymised data are available upon request from the corresponding author.
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